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Response to locoregional treatment and alpha-fetoprotein trend in
liver transplant candidates for HCC: Dwarfs standing on the
shoulders of giants
demonstrating that response to LRT works well independently
from the stage.
We agree on the Zurich Conference recommendations [4]: The
preoperative assessment of the size of largest tumor or total
diameter remains crucial. However, pre-operative radiological
staging for MC-IN and MC-OUT patients may differ in both direc-
tions in up to 25% of cases when compared to post-transplant his-
topathology [5]. Although response to LRTs has already been
shown in the beginning of the nineties as a useful tool for the
selection of HCC patients as the seminal paper by Majno et al.
clearly shows [6], the delayed introduction in clinical practice
of standardized and effective LRT techniques (TACE, radiofre-
quency ablation, radio-embolization) has hampered their routine
use in the pre-LT management of HCC. As a consequence, the
evaluation of the prognostic role of response after LRT has only
recently been implemented.
Mehta and Yao synthesized that there is ‘‘growing evidence
that size and number tell only a partial tale of the tumor charac-
JOURNAL OF HEPATOLOGYTo the Editor:
We read with great interest the correspondence on the paper
published by Otto et al., [1] on the response to repeated trans-
arterial chemo-embolization (TACE) as a discriminating tool for
selection of liver transplant (LT) candidates with hepatocellular
carcinoma (HCC). Paul et al. [2] evidenced the relative small sam-
ple size and the lack of information on the role of TACE on wait-
ing-list dropout. Our aim is to support the results obtained by
Otto et al. with the strength and the statistical power of a new
recently published European study.
Using prospectively recorded data from 6 Centers with
different allocation systems, we have conﬁrmed the role of the
response to locoregional treatments (LRT) as predictor of survival
and HCC recurrence [3]. mRECIST progression after LRT and
alpha-fetoprotein (AFP) slope >15 ng/ml/month resulted inde-
pendent predictors not only in 116 Milan-criteria (MC)-OUT,
but also in 306 MC-IN patients. Moreover, no TACE alone but also
different LRTs were performed in the routine pre-LT workout,Journal of Hepatology 2014 vol. 60 j 1325–1333 1331
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teristics that predict post-transplant recurrence’’ [7]. It is not
known yet if LRTs represent per se a surrogate of tumor biology
or if LRT works only through the proof of time. On this scope,
we recently demonstrated that ‘‘fast track’’ LT does not allow to
time the selection patients according to tumor aggressiveness [8].
We recognize some limitations. Both the studies by Otto et al.
and Lai et al. did not investigate the effect of LRT on the dropout
during waiting-time. However, an ongoing analysis performed on
821 patients coming from the EurHeCaLT study group further
conﬁrmed the role of radiological progression as selection tool
in terms of drop-out rate [9].
Secondarily, CT scans older than 5 years are not always well
evaluated by mRECIST criteria.
In conclusion, waiting for reliable preoperative predictive
markers of both adverse outcome and response to pretransplant
treatment [10], morphologic criteria remain the giants in the
evaluation of LT candidates. Biological criteria still are the dwarfs.
However, when dwarfs climb the shoulders of giants, they have
the chance to see far, allowing longer survivals.
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For the European Hepatocellular Cancer Liver Transplant
(EurHeCaLT) Study Group
Reply to ‘‘Response to locoregional treatment and alpha-fetoprotein
trend in liver transplant candidates for HCC: Dwarfs standing
on the shoulders of giants’’
To the Editor:
I thank Dr. Lai for his letter stressing some important issues of
our recent publication [1]. With great interest I have recognized
that Dr. Lai’s analysis of the EurHeCaLT data endorse the princi-
ples of our statements in a much greater cohort of patients [2].
We have focussed on response of hepatocellular carcinomas
Letters to the Editor
1332 Journal of Hepatology 2014 vol. 60 j 1325–1333
